The patients have advanced stage cancer - stage 4 I think. So they have months not years to live.
Cohort 1: 4 patients. 1 was CR and 1 SD
Cohort 2: 4 patients. All 4 SD.
Cohort 3: 4 patients, 1 CR, 2 SD and 1 discontinued.
My assumption is the missing two in cohort 1 passed on.
Don't know what can be read into these results but I will give it a go. Its no slam dunk, but its definitely not negative. Its showing signs of efficacy. I think there will be detail in the data re immune response which will provide more clarity on efficacy. Cautious and steady as she goes is my takeout with this particular 1 of our 11 diverse studies underway.
Cheers
Ann: IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT, page-31
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |